LLY

971.8

-2.02%↓

JNJ

221.61

-0.81%↓

ABBV

203.17

-0.56%↓

UNH

367.37

+0.11%↑

AZN

181.67

-1.31%↓

LLY

971.8

-2.02%↓

JNJ

221.61

-0.81%↓

ABBV

203.17

-0.56%↓

UNH

367.37

+0.11%↑

AZN

181.67

-1.31%↓

LLY

971.8

-2.02%↓

JNJ

221.61

-0.81%↓

ABBV

203.17

-0.56%↓

UNH

367.37

+0.11%↑

AZN

181.67

-1.31%↓

LLY

971.8

-2.02%↓

JNJ

221.61

-0.81%↓

ABBV

203.17

-0.56%↓

UNH

367.37

+0.11%↑

AZN

181.67

-1.31%↓

LLY

971.8

-2.02%↓

JNJ

221.61

-0.81%↓

ABBV

203.17

-0.56%↓

UNH

367.37

+0.11%↑

AZN

181.67

-1.31%↓

Home・Aktien・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Open

BrancheGesundheitswesen

19.04 -10.57

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

18.85

Max

21.25

Schlüsselkennzahlen
By Trading Economics
Einkommen	-14M -50M
Verkäufe	12M 128M
Gewinnspanne	-39.506
Angestellte	1,784
EBITDA	-17M -48M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+66.21% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	174M 2.4B
Vorheriger Eröffnungskurs	29.61
Vorheriger Schlusskurs	19.04

Nachrichtenstimmung

By Acuity

43%

57%

165 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

28.13 / 31.12 Unterstützung & Widerstand

Zai Lab Ltd ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Zai Lab Ltd ADR Prognose

Kursziel

By TipRanks

66.21% Vorteil

12-Monats-Prognose

Durchschnitt 35.27 USD 66.21%

Hoch 47 USD

Tief 21.8 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zai Lab Ltd ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Zai Lab Ltd ADR – Dist abgegeben haben.

Technischer Score

By Trading Central

28.13 / 31.12Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Stimmung

By Acuity

165 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.